These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 7690326)

  • 1. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
    Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
    Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
    Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
    J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide engineering allows cytotoxic T-cell vaccination against human papilloma virus tumour antigen, E6.
    Lipford GB; Bauer S; Wagner H; Heeg K
    Immunology; 1995 Feb; 84(2):298-303. PubMed ID: 7751006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
    Peng S; Frazer IH; Fernando GJ; Zhou J
    Virology; 1998 Jan; 240(1):147-57. PubMed ID: 9448699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.
    Feltkamp MC; Vreugdenhil GR; Vierboom MP; Ras E; van der Burg SH; ter Schegget J; Melief CJ; Kast WM
    Eur J Immunol; 1995 Sep; 25(9):2638-42. PubMed ID: 7589138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope.
    Gao L; Walter J; Travers P; Stauss H; Chain BM
    J Immunol; 1995 Dec; 155(12):5519-26. PubMed ID: 7499833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
    Castellanos MR; Hayes RL; Maiman MA
    Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
    Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
    Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
    J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
    Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
    Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.
    Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E
    Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens.
    Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S
    Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
    Herd KA; Harvey T; Khromykh AA; Tindle RW
    Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
    Kuhröber A; Schirmbeck R; Reimann J
    Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein.
    Sadovnikova E; Zhu X; Collins SM; Zhou J; Vousden K; Crawford L; Beverley P; Stauss HJ
    Int Immunol; 1994 Feb; 6(2):289-96. PubMed ID: 7512375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope.
    Vierboom MP; Feltkamp MC; Neisig A; Drijfhout JW; ter Schegget J; Neefjes JJ; Melief CJ; Kast WM
    J Immunother; 1998 Nov; 21(6):399-408. PubMed ID: 9807734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.